Navigation Links
VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations

CHARLESTON, S.C., Nov. 9, 2011 /PRNewswire/ -- VaxyGen Assay Services, LLC, today announced that it has commenced business operations, providing custom assay services, immunoassays, and database services in support of biopharmaceutical and vaccine development. The Company offers customized solutions to meet basic, applied, and clinical research demands, providing unique in vitro assays in support of research and development of novel biopharmaceutical and vaccine products operating through its GLP compliant laboratory facilities to support biomarker/immunoassay evaluation and development needs.

Commenting on the launch of VaxyGen Assay Services, David Dodd, CEO, stated, "We believe that our clients are best served through the successful combination of the highest expertise and support of science and business.  Our clients are committed to delivering innovative, life enhancing products.  VaxyGen Assay Services was founded to ensure that our clients can consistently rely on us to deliver them the highest quality client service and scientific service in support of their biological assay service needs.  Our Management Team reflects this commitment – most importantly, through their demonstrated experience in delivering such value to clients."

Leading the scientific and technical expertise at VaxyGen Assay Services is Joseph E. Martinez, Ph.D., a recognized expert in flow cytometry and multiplexed immunoassay development. Joseph is a research biologist with 25 years of flow cytometry experience. Prior to the formation of the VaxyGen family of companies, he spent 13 years as the head of the flow cytometry laboratory within the Respiratory Diseases Section at the Centers for Disease Control and Prevention. He has served as the Director of Research and Laboratory Services for several biotech companies. He has developed multiplexed immunological assays for the flow cytometric, Luminex, and ELISA platforms. Dr. Martinez is the lead inventor for US patents related to multiplex immunoassays, and is a co-inventor for an immunological adjunct molecule.

About VaxyGen Assay Services, LLC & VaxyGen Holdings, LLC

VaxyGen Assay Services ( is a member of the VaxyGen Holdings, LLC ( family of companies, consisting of VaxyGen Vaccines, Ltd., VaxyGen Manufacturing Services, LLC, VaxyGen Assay Services, LLC and, VaxyGen Management Company, LLC.  In June, 2011, the formation of VaxyGen Vaccines, Ltd., was announced in conjunction with an exclusive strategic agreement signed with the Serum Institute of India (, providing a novel, new vaccine business focused on delivering affordable innovation to improve immunization against life threatening conditions.  In October, 2011, the formation of VaxyGen Manufacturing Services, LLC was announced in conjunction with an exclusive agreement signed with the Georgia State University Research Foundation, providing a unique business collaboration with the Georgia State University Biological Process Development and Research Laboratory.

Kathryn D. Gallagher
Director, Marketing & Operations
Tel: 843.789.5924; 1.888.753.7362

SOURCE VaxyGen Assay Services, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
2. Early Adopter of INFORM HER2 Dual ISH Assay Optimistic About Impact on Patient Care, Hospital Bottom Line
3. Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria
4. NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay
5. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
6. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
7. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
8. Calipers Microfluidic Technologies Enable 510(k) Approved Multiplexed Immunoassay System for Liver Cancer Risk Assessment
9. Reimbursement Rate Nearly Tripled for Cylexs ImmuKnow® Assay
10. Prodesse ProAdeno™+ Assay Cleared for US Marketing by FDA
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") ( ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):